CYP cynata therapeutics limited

9.68%

17.0¢

"By focusing on trial start time I think you are focusing on...

First 199 Last

Share
Profile

Follow
Pledge

8,722 Posts.

1455

07/12/22

13:06

Post #: 65196933
Share

Originally posted by JB1975: ↑

By focusing on trial start time I think you are focusing on something that has no inherent value. And if management slips a deadline (to the extent the end of year was a created expectation by them) I think you'd be mistaken if you think shareholders are going to be surprised about that.

It doesn't matter when the trial starts (in my opinion) it matter when it finishes (or when some scientifically meaningful further results become known). It would be better not to start this year then to start this year without having a good basis for confidence that recruitment can be done in a timely manner. It also could be better to never start if there is never a good chance of a successful finish. A successful finish will depend on estimating recruiting rates from centers in different countries - yes presumably the US will be a significant part of that - but forecasting, in my opinion, should also consider whether centres will be able to get patients to accept a protocol where a third of them will get standard of care only - which is like a commitment to no other experimental therapies. Personally I found it a bit persuasive that experts not directly related to MSB (ie other than Joanne Kurtzberg) also gave evidence that recruiting in Europe for GvHD had been difficult - indeed caused a trial to not go ahead, because patients or doctors of patients wouldn't accept the chances of patients getting in the control arm.

From comments at the AGM its clear that the company is being more careful about recruitment planning than they were with MEND. Will they be careful enough - I don't know. For the most part shareholders are kept in the dark on details.

To answer your question on likelihood, one would nearly need to do the planning exercise I hope the company is doing. I.e contact centres that have historically treated patients for cancers etc and so have had streams of people getting GvHD and talk to them about historical rates and about the chances of the protocol being recruited into with the control arm.

Alternatively you could ring/email the company and ask.

Expand

"By focusing on trial start time I think you are focusing on something that has no inherent value."

Then why does CYP keep making announcements nominating the expected start time?

Do you need me to show you where they (not me!) have done that many times?

CYP Price at posting: 31.0¢ Sentiment: None Disclosure: Not Held
2 Upvote

1 Great analysis

Reply

Top Stories

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

AII

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

First 199 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 17.0¢		Change 0.015(9.68%)		Mkt cap ! $38.41M

Open	High	Low	Value	Volume
15.5¢	17.0¢	15.5¢	$47.10K	289.1K

Buyers (Bids)

No.	Vol.	Price($)
1	50000	16.5¢

Sellers (Offers)

Price($)	Vol.	No.
17.0¢	23813	3

View Market Depth

No.	Vol.	Price($)
1	50000	0.165
4	47240	0.155
4	161673	0.150
1	5000	0.145
2	45000	0.140

Price($)	Vol.	No.
0.170	18813	2
0.175	55250	1
0.180	62619	3
0.185	35990	1
0.195	19300	1

Last trade - 16.10pm 27/06/2025 (20 minute delay)

CYP (ASX) Chart

"By focusing on trial start time I think you are focusing on...

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Monash IVF shares cater 25% – Disaster or deep-value play?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

"By focusing on trial start time I think you are focusing on...

Top Stories

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Monash IVF shares cater 25% – Disaster or deep-value play?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News